# SpyGlass Ophthalmics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spyglass-ophthalmics

- Industry: Medical Devices & Equipment
- Headquarters: Mission Viejo, US
- Website: www.spyglassophthalmics.com
- Total disclosed funding: $34M
- Latest round: Series B (Dec 29, 2020)
- Investors on record: 2

## About

SpyGlass Ophthalmics Inc. is an innovative ophthalmic therapeutics company focused on developing advanced treatment platforms for chronic eye diseases, aiming to improve patient outcomes and quality of life in the ophthalmology sector.Founded in 2019 and headquartered in Mission Viejo, US, SpyGlass Ophthalmics Inc. specializes in creating therapeutic solutions for chronic ophthalmic conditions. The company has engaged in two investment deals, with the latest being a Series B funding round raised on December 29, 2020, amounting to USD 27.5 mn led by Vensana Capital, alongside New Enterprise Associates and additional investors. The firm was established by a team with prior experience in the ophthalmic sector.SpyGlass Ophthalmics (SGO) specializes in developing innovative therapeutic technologies aimed at treating chronic ophthalmic diseases. Its core products focus on addressing significant unmet medical needs in ophthalmology, targeting healthcare institutions and clinics, as well as patients seeking effective treatment solutions. The company operates in various markets where chronic eye diseases are prevalent, ensuring that its advanced technologies reach those in need.SpyGlass Ophthalmics has secured USD 27.5 mn in Series B financing which will support its developmental initiatives. The company's revenue model is primarily based on partnerships with healthcare providers and investors, involving business-to-business transactions for the supply of patented technologies. Revenue may be generated through licensing agreements and direct sales to specialized ophthalmology clinics, although specific pricing details are not disclosed.With the recent Series B funding round completed in December 2020, SpyGlass Ophthalmics plans to expand its product offerings and enhance its market presence. The company is working on new therapeutic products designed to meet the needs of patients with chronic eye diseases. Additionally, it aims to enter new geographic markets where chronic conditions are prevalent and the infrastructure supports advanced therapies, leveraging the USD 27.5 mn raised to drive these initiatives.

## Funding rounds

- Series B, Dec 29, 2020, $28M — New Enterprise Associates, Vensana Capital
- Series A, May 1, 2019, $6M — New Enterprise Associates

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series B